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Abstract 26 
As the history of the cord-blood banking system has lengthened, the number of 27 
cord-blood units (CBUs) cryopreserved for years has increased. The global expansion of 28 
cord-blood banking resulted in active international exchange of CBUs. To determine whether 29 
long-term cryopreservation and international shipment of CBUs affect the quality of the units 30 
and outcome after transplantation, we retrospectively analyzed the quality of 95 CBUs and the 31 
hematologic recovery of 127 patients with hematological malignancy following single-unit 32 
cord-blood transplantation. Of the 127 CBUs used to transplant, 42 units were cryopreserved 33 
for long periods (5-11.8 years), and 44 units were shipped from distant countries. We found 34 
that length of cryopreservation and origin of CBUs did not affect the ratio of viable total-35 
nucleated cells after thawing. Also, neutrophil engraftment was not affected by long-term 36 
cryopreservation (> 5 years) or origin (from distant countries), (hazard ratio, 0.91 and 1.2; P = 37 
0.65 and 0.41; respectively). The number of CD34+ cells before freezing (> 1.4 cells/kg 38 
recipient) was the only factor which enhanced neutrophil engraftment (hazard ratio, 1.8; P < 39 
0.01). This suggests that length of cryopreservation and origin need not be prioritized over the 40 
CD34+ cell dose when selecting CBUs.  41 
 42 
 4 
Introduction 43 
Recent studies have shown that the number of umbilical cord-blood transplantations 44 
(CBT) has been steadily increasing, and the outcomes of CBT are getting closer to those 45 
obtained from bone marrow transplantation.1-3 Over the past 20 years, a worldwide large-scale 46 
cord-blood banking system has enabled immediate access to cryopreserved cord-blood units 47 
(CBUs) for patients who require an alternative stem cell source for transplantation. As the 48 
history of the cord-blood banking system becomes longer, the number of cord-blood units 49 
which are cryopreserved for years has increased.4 Global expansion of this banking has 50 
resulted in active international exchange of CBUs; > 40% of CBUs are shipped beyond 51 
country borders.5 52 
Although long-term preservation of cord blood was shown to not influence 53 
hematopoietic reconstitution potential in the mouse model,6,7 it is unclear whether 54 
preservation length has an impact on hematologic recovery following CBT in humans.  The 55 
fact that not all banks have adopted international guidelines,4 such as NetCord-FACT 56 
International Standards,8 raises an additional issue, the potential difference among banks in 57 
quality control, which might result in impairment of reconstitution potential during a 58 
prolonged period of cryopreservation or international shipment. Moreover, incomplete 59 
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standardization of the processing method for cord blood9 provokes questions about whether 60 
bank-provided information such as number of CD34+ cells reflects clinical outcomes after 61 
CBT.  62 
The aim of this study is to evaluate the effect of long-term cryopreservation of 63 
CBUs and the region of the banks from which the cord blood originates on the quality of 64 
CBUs and hematologic recovery after CBT.  We retrospectively analyzed the quality of 95 65 
units obtained from various countries, and hematological recovery in 127 CBTs. Also, we 66 
investigated whether information about the pre-freezing CBUs that is issued by banks stays 67 
reliable and can predict the clinical outcome regardless of the length of cryopreservation or 68 
the origin of the units. 69 
 70 
Subjects and Methods 71 
Cord blood units 72 
CBUs were selected to infuse the most closely matched donor unit/recipient pair: 73 
minimum requirements were 4/6 considering difference for HLA-A, B, and DRB1. CBUs 74 
with greater than 1.0 × 107 cells/kg recipient-body weight of total nucleated cells (TNCs) 75 
were selected. Units from the following countries were used in San Martino Hospital (Genoa, 76 
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Italy): the United States (40), Italy (25), Germany (10), Australia (8), France (5), Belgium (3), 77 
Spain (2), Brazil (1), and Taiwan (1). Units of domestic origin were transplanted in University 78 
of Tsukuba Hospital (Tsukuba, Japan). 79 
 80 
Measurement of TNCs and CD34+ cells 81 
95 CBUs used in San Martino Hospital were analyzed. Before transplant, each cord 82 
blood unit was thawed at 37°C and cells were washed according to the Rubinstein method.10 83 
Then, cells were resuspended in 20 mL of thawing solution (saline solution + 5% dextran + 84 
2.5% human albumin). A sample of the final volume was used for quality controls: TNC count 85 
and CD34+ cell numbers. Nucleated cells were counted using a Neubauer chamber for the 86 
WBC counting; CD34+ cell numbers were evaluated by flow cytometry. Samples were stained 87 
with the following antibodies: PE-conjugated anti-CD34 and FITC-conjugated anti-CD45. 88 
Nucleic acid dye 7-aminoactinomycin D was used to distinguish dead cells. Flow cytometry 89 
was performed using a FACSCalibur instrument (Beckton Dickinson, San Jose, CA, USA), 90 
and the Cell Quest software was used for analysis. The CD34+ subpopulation was identified 91 
by co-staining of CD45, according to the single platform guidelines of the International 92 
Society of Hematotherapy and Graft Engineering (ISHAGE).11 The recovery rates of TNCs 93 
 7 
and CD34+ cells were determined as the ratios of each post-thawing cell number measured in 94 
San Martino Hospital and the pre-freezing cell number provided by each bank. 95 
 96 
Patients and Transplant Procedures 97 
127 consecutive CBTs performed on adult patients with hematologic malignancies 98 
from April 2007 to September 2014 were retrospectively analyzed. 83 were transplanted in 99 
San Martino Hospital and 44 were transplanted in University of Tsukuba Hospital. Patients 100 
were prepared for transplant with myeloablative conditioning for younger patients or reduced-101 
intensity conditioning for older patients or those with comorbidities. Cord blood were 102 
transplanted into the bone marrow in 92 cases, or intravenously in 35 cases. Granulocyte 103 
colony-stimulating factor was given after transplant until neutrophil recovery. The time of 104 
neutrophil engraftment was defined as the first day of three consecutive days after 105 
transplantation when the absolute neutrophil count was maintained at 0.5 × 109 /L or higher. 106 
The time of platelet engraftment was defined as the first day of seven consecutive days when 107 
the platelet count was maintained at 20 × 109 /L or higher without transfusion support. Graft 108 
failure was defined as no sign of hematological recovery by post-transplant day 100. 109 
 110 
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Statistical analysis 111 
Recovery rates of TNCs and CD34+ cells were evaluated with the student-t for 112 
length of cryopreservation and bank of origin. Cumulative incidence of neutrophil and platelet 113 
recovery was assessed with the Gray test, with deaths from other causes as competing risk 114 
factors.12 Multivariate analyses were performed with the Fine and Gray proportional hazards 115 
regression model. All p values were two-sided with type I error fixed at 0.05. Statistical 116 
analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, 117 
Saitama, Japan),13 a graphical user interface for R (R Foundation for Statistical Computing, 118 
Vienna, Austria. Version 3.0.2). 119 
 120 
Result  121 
The median cryopreservation period of 127 CBUs was 3.2 (range, 0.1 to 11.8) 122 
years. The median number of TNCs and CD34+ cells before cryopreservation were 2.0 × 109 123 
(range, 0.9 to 4.5) cells and 7.5 × 106 (range, 2.1 to 27), respectively.  124 
To analyze the influence of the length of cryopreservation, we divided the evaluable 125 
95 cord blood units into 50 “younger” units, which were cryopreserved for less than 5 years, 126 
and 45 “older” units, which were cryopreserved for more than 5 years. The TNC recovery rate 127 
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of younger and older units was 74.2 ± 18.9% and 76.1 ± 15.6%, respectively (p = 0.61, Figure 128 
1A). The mean difference was 1.9 (95% CI, -5.5 to 9.2). Also, the CD34+-cell recovery rate of 129 
older units (74.3 ± 28.1%) was not different from that of younger units (76.2 ± 34.6%) (p = 130 
0.79, Figure 2A). The mean difference was -1.9 (95% CI, -15.9 to 12.1). Next, we analyzed 131 
the influence of region of bank on the quality of CBUs.  TNC recovery rates of units from 132 
European countries, and other distant countries were 74.8 ± 17.4%, and 75.3 ± 17.5%, 133 
respectively. The mean difference was 0.5 (95% CI, -6.9 to 7.9). CD34+-cell recovery was 134 
76.7 ± 30.7%, and 73.9 ± 32.7%, respectively. The mean difference was -2.8 (95% CI, -16.7 135 
to 11.1). Hence, distance between the transplant facility and banks did not have statistically 136 
significant impact on recovery of TNCs and CD34+ cells (p = 0.89 and 0.69, respectively). 137 
The correlation coefficients between pre-freezing and post-thawing numbers of TNCs and 138 
CD34+ cells were not different regardless of the length of cryopreservation and the origin 139 
(data now shown).  140 
Overall cumulative incidence of neutrophil engraftment was 86% (95% CI, 78 to 141 
91)  and median neutrophil engraftment day was day 23 in 127 evaluable patients following 142 
CBT performed in Genoa and Tsukuba. Of the 127 CBUs used to transplant, 42 units were 143 
cryopreserved over 5 years (5 to 11.8 years), and 44 units were shipped from distant countries. 144 
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When we compared the cumulative incidence of neutrophil engraftment after CBT, length of 145 
cryopreservation did not have a significant impact (84% vs 91%; p = 0.95, Figure 2A). 146 
Moreover, neutrophil recovery after CBT with units from distant countries was not different 147 
from that with domestic and neighboring country-origin units (European-origin units used in 148 
Genoa and Japanese-origin units used in Tsukuba)  (84% vs 87%; p = 0.66, Figure 2B). In our 149 
series of transplants, the pre-freezing number of TNCs per recipient body weight did not 150 
influence neutrophil recovery, namely, cumulative engraftment of patients receiving units of 151 
larger and smaller than 2.5 × 107 /kg TNCs were 86% and 85% respectively (p = 0.36; Figure 152 
2C). On the other hand, a pre-freezing CD34+ cell dose larger than 1.4 × 105 /kg significantly 153 
promoted neutrophil recovery (p = 0.002, Figure 2D), namely, cumulative incidence and 154 
median day of engraftment were 92% (95% CI, 79 to 97) and day 21 in the larger CD34+ cell 155 
dose group, and 81% (95% CI, 70 to 88) and day 25 in the smaller CD34+ cell dose group, 156 
respectively.  157 
 In the multivariate models, more than 1.4 × 105 /kg recipient body weight of pre-158 
freezing CD34+ cell dose was the unique variable affecting neutrophil recovery (hazard ratio 159 
1.8; 95% CI, 1.2 to 2.8, p = 0.005, Table 1), and platelet recovery (hazard ratio, 2.0; 95% CI, 160 
1.3 to 3.0, p = 0.002, data not shown). HLA compatibility or intensity of conditioning 161 
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regimens did not have any impact on neutrophil and platelet recovery in both univariate and 162 
multivariate analysis (data not shown). 163 
 164 
Discussion 165 
As the history of CB banking has become longer, the number of cord blood units 166 
stored for more than a decade has increased,14 while whether or not there is an expiration date 167 
for cord blood units has been unclear. In addition, the system of cord blood banking have 168 
spread worldwide, and over 40% of cord blood units is currently exported to another country.5 169 
Not all banks are yet accredited by global standards such as NetCord-FACT International 170 
Standards,8 and, moreover, long-distant transportation from banks could affect cord blood 171 
quality.15 Marked differences in the CD34+ cell viability of units obtained from different 172 
individual CB banks were demonstrated16 and more than 10% of units was reported to have 173 
quality problems that might be a risk for patients undergoing CBT.15 Thus the influence of 174 
long-term cryopreservation and bank origin need to be investigated to know whether the units 175 
remain useful for clinical use.   176 
The number of TNCs and CD34+ cells is a good indicator of cord blood quality, 177 
because these have been reported to be associated with engraftment.17,18 However, is the 178 
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information about the pre-freezing number of cells reliable? The information provided by 179 
banks might not reflect actually infused viable cells, because various factors could influence 180 
the cell viability, such as long-term cryopreservation, impaired quality control during 181 
cryopreservation, and long-distance shipment of cord blood units. Previous studies showed 182 
that long-term cryopreservation did not compromise the number of hematopoietic progenitor 183 
cells for up to 12 years,19 nor recovery of TNCs and CD34+ cells of CBUs.20 But in those 184 
studies conditions of cryopreservation were homogeneous, which may not mimic the actual 185 
banking system in which preservation conditions may differ from bank to bank. We measured 186 
post-thawing TNC and CD34+-cell doses in each unit by a standardized method. Deterioration 187 
of viability and dispersion of the bank-provided cell dose can result in alteration in the 188 
recovery rate of TNCs and CD34+ cells, which is the ratio between the pre-freezing and post-189 
thawing values. That is why we chose the recovery rate as a quality indicator of cord blood 190 
units. Consequently, recovery rates of TNCs and CD34+ cells were not statistically different 191 
regardless of length of cryopreservation or distance between the transplant facility and banks 192 
With regard to the function of long-term cryopreserved units, the hematopoietic 193 
reconstitution potential of CB cells stored for 15 years,6 and for up to 23.5 years7 has been 194 
proved by in vitro assay and transplantation in immunodeficient mice. It has been reported 195 
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that long-term cryopreservation did not influence hematological recovery after CBT using 196 
units of at most 5 years old21 and by analysis of child recipients,22 although these data are 197 
based on a limited number of cases. Our retrospective study provides confirmative 198 
information that length of cryopreservation for up to 11.8 years, and bank of origin had little 199 
impact on engraftment ability in adult recipients. In addition, these results implied that the 200 
quality control of banks is working well.  201 
 Since cord blood was transplanted directly into the bone marrow in majority of our 202 
cases,23 the homing capacity of hematopoietic stem cells could not fully be evaluated by this 203 
study. Although equivalence of TNC recovery rate could be shown, our sample size might not 204 
be large enough to strictly prove equivalence in CD34+ cell recovery in Figure 1, judged from 205 
the relative wideness of 95% CIs of the mean differences. Moreover, we could not exclude 206 
potential selection bias because our study was a retrospective analysis. Further large-scale 207 
prospective multicenter analysis is needed.  208 
 In conclusion, the factor that had impact on hematological recovery after CBT in 209 
adults was neither length of cryopreservation nor bank of origin, but instead the number of 210 
pre-freezing CD34+ cells provided by the cord blood bank. Given that the recovery rate of 211 
TNCs and CD34+ cells after thawing, and engraftment serve as indicators of cord blood 212 
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quality, quality control is working well regardless of length of cryopreservation or bank of 213 
origin. These results provide the useful information that the number of pre-freezing CD34+ 214 
cells provided by banks is reliable and can serve as a basis for selection of suitable cord blood 215 
units. 216 
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Figure Legends 228 
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Figure 1. Influence of length of cryopreservation and banks of origin on recovery rate of 230 
TNCs and CD34+ cells 231 
Recovery rates of total nucleated cells and CD34+ cells were calculated as the post-thawing 232 
cell number divided by the pre-freezing counterpart provided by the cord blood bank. 233 
Influence of the length of cryopreservation (more or less than 5.0 years, A and B) and 234 
influence of bank of origin (European countries or other distant countries, C and D) are 235 
shown. TNCs, total nucleated cells. 236 
 237 
Figure 2. Univariate analysis of effect of cord blood units-characteristics on neutrophil 238 
engraftment 239 
Influence of the length of cryopreservation (A), the bank of origin (B), the number of pre-240 
freezing total nucleated cells per recipient’s body weight (C), and number of pre-freezing 241 
CD34+ cells per recipient’s body weight (D) on neutrophil engraftment after cord blood 242 
transplant. The “domestic” group includes neighboring country-origin units in B. TNCs, total 243 
nucleated cells.  244 
 245 
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Table 1. Predictors impacting neutrophils engraftment in multivariate analysis
Hazard ratio (95% CI) P-value
Length of cryopreservation (years) < 5.0 1
> 5.0 0.91 (0.62-1.4) 0.65
Banks of origin domestic or neibouring countries 1
distant countries 1.2 (0.79-1.8) 0.41
Pre-freezing  TNCs (x 107 /kg) < 2.5 1
> 2.5 1.1 (0.73-1.6) 0.70
Pre-freezing  CD34+ cells (x 105 /kg) < 1.4 1
> 1.4 1.8 (1.2-2.8) 0.005
